CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Epi Biotech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Epi Biotech Co Ltd
162-1, Songdo-dong, Yeonsu-gu
Phone: +82 327494506p:+82 327494506 INCHEON, 21984  South Korea Ticker: 446440446440

Business Summary
Epi Biotech Co Ltd is a Korea-based company principally engaged in the research, development and supply of biopharmaceuticals. The Company is principally engaged in the research, development and supply of biopharmaceuticals such as cell therapy products and diagnostic products. In addition, the Company is engaged in the provision of contract development and manufacturing organization (CDMO) services.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023-----

General Information
Number of Employees: 25 (As of 12/31/2023)
Outstanding Shares: 2,297,504 (As of 12/31/2023)
Shareholders: 104
Stock Exchange: KON
Fax Number: +82 322098239
Email Address: info@epibiotech.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 1, 2024